How to Value an Independent Radiology Group in 2026

Radiology group M&A has been the single most active corner of physician services consolidation for a decade. Radiology Partners has spent over $3 billion building the largest national platform. US Radiology Specialists(backed by Welsh Carson) has assembled a multi-state network. Regional PE-backed groups are rolling up in the Midwest and Southeast. And the buyer appetite for independent groups with strong hospital contracts hasn't really cooled, despite what you might read about rising rates and PE fatigue.

Independent radiology groups generally trade in a 5-9x EBITDA range, with the spread driven almost entirely by contract quality, RVU productivity, and subspecialty mix. The delta between a 5x deal and a 9x deal on the same group is real money — typically $8-15M on a mid-sized practice — and it comes down to how the group is structured, not just how much it earns.

The Multiples: Where Radiology Groups Trade

The consolidated market for independent radiology groups in 2026 looks roughly like this:

• 5.0-6.0x EBITDA: Small groups with subscale hospital contracts, heavy owner-physician dependency, or declining RVU trends. Typically regional buyers, not national strategics.
• 6.5-7.5x EBITDA: The middle of the market. Solid hospital contracts, reasonable subspecialty coverage, 8-20 radiologists. Radiology Partners, US Radiology, and regional PE platforms all compete here.
• 8.0-9.0x+ EBITDA: Premium assets. Exclusive multi-hospital contracts, strong subspecialty bench (neuro, breast, IR), teleradiology infrastructure, and established 24/7 coverage. Strategic platform deals.

A 15-radiologist group generating $18M in revenue and $3.5M in EBITDA after normalized physician compensation will typically transact for $22-28M in a well-run process. The same group can command $30M+ if it has an anchor exclusive contract with a major health system and a demonstrated ability to recruit.

Hospital Contracts Are the Core Asset

Let me say this as directly as I can: if you own a radiology group, what you're selling is your hospital contracts. Everything else — RVUs, teleradiology infrastructure, subspecialty depth — only matters in the context of whether it makes your contracts more defensible and renewable.

Buyers evaluate hospital contracts on four dimensions:

Exclusivity. An exclusive professional services agreement where the group is the sole provider of radiology services to the hospital is worth 1.5-2x more in multiple than a non-exclusive arrangement. Non-exclusive contracts are inherently unstable — the hospital can onboard another group or a teleradiology vendor at any time.

Remaining term. A contract with 4+ years remaining and a documented renewal history commands premium pricing. A contract that's up for renewal in 18 months creates immediate buyer anxiety — deals routinely get repriced or restructured around pending renewals.

Economic structure. Professional fee billing (group bills payers directly for the professional component) is cleaner than stipend-based arrangements where the hospital pays the group a fixed subsidy. Stipend-heavy contracts introduce hospital credit risk and are valued lower.

Health system consolidation exposure. If your primary hospital contract is with a standalone community hospital that's about to be acquired by a large system, your contract has an expiration date. Buyers know this and will price it in aggressively.

RVU Production and Per-Radiologist Economics

Radiology groups get underwritten on RVU production per full-time equivalent radiologist. The rough benchmarks I use in 2026:

• Under 8,000 wRVU/FTE/year: Under-productive. Suggests either weak volume or cultural/workflow problems.
• 10,000-12,000 wRVU/FTE/year: Market-typical productivity.
• 13,000-15,000 wRVU/FTE/year: High-performing. Indicates efficient workflow, good subspecialty routing, strong technology infrastructure.
• 15,000+ wRVU/FTE/year: Outlier territory, often driven by heavy teleradiology supplementation or unusually high-volume contracts.

Buyers pay for productivity because it's the leverage in the deal model. A group where radiologists produce 13,000 wRVUs at $45/wRVU generates significantly more revenue per FTE than one at 10,000 wRVUs — and the marginal cost of that extra production is mostly already covered by the base salary structure.

One important nuance: post-transaction, most PE-backed platforms reset physician compensation models toward productivity-based pay. This means that your group's reported EBITDA after normalizing physician compensation to market is often very different from your current reported EBITDA. Getting that normalization right in a quality of earnings is one of the highest-leverage things a sell-side advisor does.

Teleradiology and 24/7 Coverage

Teleradiology used to be a threat to independent groups. In 2026, it's table stakes — and groups that have built their own internal teleradiology infrastructure are actually worth meaningfully more than groups that outsource nights and weekends to vRad or another third-party provider.

Why? Because internal teleradiology does three things: it captures the night/ weekend professional fees that would otherwise flow to an outside vendor, it preserves service quality and referrer relationships on after-hours reads, and it demonstrates operational sophistication to acquirers. A group that can show it reads 92% of its own studies internally — including after-hours — is a more valuable platform than one that outsources 40% of its volume.

That said, building internal 24/7 coverage is genuinely hard. It requires night hawk positions, subspecialty overnight availability for stroke calls, and a PACS/ worklist infrastructure that routes studies intelligently. If you don't have it yet, that's fine — but understand that buyers will model the cost of building it and deduct it from their offer.

Subspecialty Mix and the Bench

A group's subspecialty composition drives both contract defensibility and valuation. Hospitals increasingly require their radiology partner to provide fellowship-trained subspecialty reads in neuroradiology, musculoskeletal, body, breast, and interventional. A group with that bench can renew contracts with confidence. A group without it is vulnerable to being replaced by a larger platform that can.

The subspecialties that command premium in 2026:

• Neuroradiology — critical for stroke programs and trauma centers.
• Breast imaging — MQSA compliance, screening volume, biopsy capability.
• Interventional radiology — increasingly the profit driver for groups with hospital IR suite contracts.
• Pediatric radiology — scarce and commands real premiums in markets with children's hospitals.

The AI Question

Every radiology group owner asks me some version of: "Will AI destroy my valuation?" The honest answer is no, not in the way people worry about. AI tools for detection and triage (stroke, pulmonary embolism, intracranial hemorrhage) are genuinely useful and widely deployed, but they augment radiologist workflow — they don't replace reads. What AI does affect is productivity expectations: buyers now underwrite modest productivity gains from AI tooling and expect groups to be using at least basic AI workflow tools.

The real risk isn't AI replacing radiologists. It's AI enabling larger platforms to run faster worklists and reduce per-read costs, which over time pressures the economics of subscale independent groups. The strategic response isn't to fight AI — it's to be big enough or specialized enough that you benefit from the leverage.

What Destroys Radiology Group Value

A contract renewal cliff. If your primary hospital contract is up in less than 24 months and you haven't started renewal conversations, buyers will either walk or aggressively reprice.

Founder-physician dependency. If two or three founding partners are the relationship owners with hospital administration, and they're nearing retirement, the contract is at risk. Multi-generational leadership is a valuation premium.

Recruitment failure. A group that can't recruit new radiologists has a dying asset. Buyers will want to see a 3-year hiring track record before paying premium multiples.

Productivity decline. Declining wRVU per FTE over consecutive years is a red flag that suggests either volume loss or culture problems.

How to Maximize Your Exit

Renew contracts before going to market. A fresh 5-year exclusive hospital contract is worth 1.0-1.5x of EBITDA in the multiple.

Build subspecialty depth. Hire the fellowship-trained radiologists before the sale process, not during.

Normalize physician compensation carefully. Work with an advisor who understands how PE buyers model the post-close comp structure. Getting this wrong can cost $5M+ in enterprise value.

Run a real process. Radiology Partners, US Radiology, LucidHealth, and the regional PE platforms should all be invited. Multiple bidders consistently produce 10-20% higher outcomes than negotiated deals.

Establish your baseline. Get a defensible instant valuation before the first buyer call so you know what range to anchor to.

The Bottom Line

Independent radiology group valuation in 2026 is a story about contract quality, productivity, and subspecialty depth — with AI as a background variable rather than a disruptive one. The 5-9x EBITDA range is real, but where you land depends overwhelmingly on preparation and process. Groups that enter the market with fresh hospital contracts, strong recruitment track records, and clean financials exit at multiples that feel aggressive. Groups that stumble into a sale in reaction to retiring partners or a contract loss exit at the bottom of the range, or worse. The advisors who do this well will tell you the same thing: the deal is won or lost in the 18 months before the first call with a buyer.